加载中
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
前收盘价
US$2.00
−US$0.01 · -0.50%
盘中时间采用ET。市场数据可能有所延迟。
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
日内区间
当前US$2.00
52周区间
当前US$2.00
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
12
估值过高
情绪
54
多空交织
风险
66
高风险
动量
36
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
日内区间
当前US$2.00
52周区间
当前US$2.00
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 5.6万 USD | 315.3万 USD | 50万 USD | 346.48万 USD |
| 销货成本 | — | 19.4万 USD | 9万 USD | — | 379.86万 USD |
| 毛利 | — | −13.8万 USD | 306.3万 USD | 50万 USD | −33.38万 USD |
| 研究与开发 | 1315.5万 USD | 748万 USD | 238.8万 USD | 157.31万 USD | 379.86万 USD |
| 销售、一般及管理费用 | 1099.7万 USD | 943万 USD | 389.4万 USD | 128.88万 USD | 129.77万 USD |
| 营业费用 | 2402.2万 USD | 1691万 USD | 619.2万 USD | 277.04万 USD | 129.77万 USD |
| 利息收入 | — | — | — | 1757 USD | 1.09万 USD |
| 利息支出 | 21.3万 USD | 52.6万 USD | 55.8万 USD | 1.59万 USD | 3094 USD |
| 折旧和摊销 | 7.3万 USD | 19.4万 USD | 9万 USD | 6.13万 USD | 3.34万 USD |
| 营业利润 | −2402.2万 USD | −1704.8万 USD | −312.9万 USD | −227.04万 USD | −163.15万 USD |
| 净利润 | −1918.2万 USD | −1114.1万 USD | 526.9万 USD | −268.21万 USD | −126.47万 USD |
公司数据更新于 2026年10月11日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
